Targeted remodelling of the diseased lung with biopharmaceutical agents. Fall 08 By Dr Edward E. Berger Emphysema is a progressive, debilitating disease that affects approximately 4.1 million people in the United States1 or roughly 1% of the US population2. The disease is characterised by d... Read more...

HIV Therapy past, present and future. Summer 08 By Dr Laura Waters Since the identification of HIV in 1983 and licensing of AZT in 1986 we now have more than 20 agents available for HIV treatment from five drug classes. This article will review recent ad... Read more...

DO NOT GO GENTLE – urinary troubles for more than the ageing. Fall 2003 By Dr Anthony PDW Ford The needs of younger incontinence sufferers coupled with the ageing of the baby-boomer population portend a big boost in demand for effective and welltolerated new medicines for lower uri... Read more...

Transcending Proteasome Inhibition for the Treatment of Cancer. Summer 08 By Dr Mark Rolfe Healthy cellular function requires a carefully controlled balance between protein synthesis and protein degradation, a process known as protein homeostasis. The major intracellular pathwa... Read more...

New developments in antigen-specific immunotherapies Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer. Spring 2003 By Dr Jörg Schneider and Professor Andrew J. McMichael Vaccination has been used effectively for more than 200 years to protect individuals from a range of infectious diseases such as polio and smallpox. Many academic and commercial groups ar... Read more...

Is amyloid-related toxicity an inevitable consequence of ageing? Spring 08 By Dr J Mark Treherne and Dr David IC Scopes Amyloid-related toxicity need not necessarily be the inevitable consequence of ageing, if some of the new drug discovery strategies to treat neurodegenerative and other ageing-related dis... Read more...